US11253541B2 - Method of inhibiting inflammatory response using lipopolysaccharide of Parabacteroides goldsteinii - Google Patents

Method of inhibiting inflammatory response using lipopolysaccharide of Parabacteroides goldsteinii Download PDF

Info

Publication number
US11253541B2
US11253541B2 US16/747,904 US202016747904A US11253541B2 US 11253541 B2 US11253541 B2 US 11253541B2 US 202016747904 A US202016747904 A US 202016747904A US 11253541 B2 US11253541 B2 US 11253541B2
Authority
US
United States
Prior art keywords
lipopolysaccharide
parabacteroides goldsteinii
cells
present
peripheral blood
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
US16/747,904
Other versions
US20200237806A1 (en
Inventor
Tzu-Lung Lin
Po-I Wu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Multistars Biotechnology Co Ltd
Original Assignee
Multistars Biotechnology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from TW108148713A external-priority patent/TWI716249B/en
Application filed by Multistars Biotechnology Co Ltd filed Critical Multistars Biotechnology Co Ltd
Priority to US16/747,904 priority Critical patent/US11253541B2/en
Assigned to Multistars Biotechnology Company Limited reassignment Multistars Biotechnology Company Limited ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: LIN, TZU-LUNG, WU, PO-I
Publication of US20200237806A1 publication Critical patent/US20200237806A1/en
Application granted granted Critical
Publication of US11253541B2 publication Critical patent/US11253541B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/739—Lipopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the present invention relates to a method of using a lipopolysaccharide of Parabacteroides goldsteinii , in particular to the use of the lipopolysaccharide of Parabacteroides goldsteinii to inhibit inflammatory response; wherein, the lipopolysaccharide of Parabacteroides goldsteinii can effectively inhibit the immune response of peripheral blood mononuclear cells, macrophages and/or B cells to effectively inhibit the occurrence of inflammatory response.
  • Inflammatory response is a defensive response of vascular system tissues to inflammatory factors and local damage. It is mainly a physiological response triggered by stimuli such as trauma, bleeding or pathogen infection, including symptoms of redness, swelling, fever, pain, etc. Inflammatory response is a protective measure of the innate immune system to remove harmful stimuli or pathogens and promote tissue repair. Usually, the inflammatory response is beneficial.
  • LPS Lipopolysaccharide
  • a microorganism When a microorganism invades an individual and releases a large amount of lipopolysaccharide, it stimulates immune cells to secrete a large number of cytokine that promote inflammatory response, such as tumor necrosis factor- ⁇ (TNF- ⁇ ), interleukin-1 (Interleukin-1, IL-1), etc., and cause individuals to produce excessive inflammatory response, and even lead to the occurrence of sepsis, the most serious may be fatal, and the biological response induced by lipopolysaccharide is considered to be the main cause of sepsis.
  • TNF- ⁇ tumor necrosis factor- ⁇
  • Interleukin-1 Interleukin-1
  • IL-1 interleukin-1
  • One objective of the present invention is to provide a method of inhibiting an inflammatory response, comprising administering to a subject in need thereof a composition comprising an effective amount of a lipopolysaccharide of a Parabacteroides goldsteinii.
  • the lipopolysaccharide of the Parabacteroides goldsteinii inhibits an immune response of a peripheral blood mononuclear cell and inhibits the peripheral blood mononuclear cell secretes a cytokine.
  • the lipopolysaccharide of the Parabacteroides goldsteinii inhibits an immune response of a macrophage and inhibits the macrophage secretes a cytokine.
  • the lipopolysaccharide of the Parabacteroides goldsteinii inhibits an immune response of a B cell and inhibits the B cell differentiates or secretes a cytokine.
  • the inflammatory response is induced by a pathogenic lipopolysaccharide, and the pathogenic lipopolysaccharide is from an Escherichia coli.
  • the Parabacteroides goldsteinii is Parabacteroides goldsteinii DSM32939.
  • the use of the lipopolysaccharide of the Parabacteroides goldsteinii of the present invention in the inhibition of inflammatory response can be, but is not limited to, oral administration to the subject in need thereof.
  • the composition can be orally administered along with food; therefore, the preparation of the composition comprising the Parabacteroides goldsteinii of the present invention can further include a protein, a monosaccharide, a disaccharide, an oligosaccharide, an oligosaccharide, a polysaccharide, a carbohydrate, an amino acid, a lipid, a vitamin, or any combination thereof, and the composition further comprises a pharmaceutically acceptable excipient, carrier, adjuvant, and/or food additive.
  • the preparation of the composition comprising the lipopolysaccharide of the Parabacteroides goldsteinii of the present invention can further comprise a pharmaceutically acceptable carrier or another adjuvant well-known in the art.
  • the composition is in the form of, but is not limited to, a spray gas, a solution, a semi-solid, a solid, a gelatin capsule, a soft capsule, a tablet, an oral strip, a chewing gum, and/or a freeze-dried powder in order to deliver the lipopolysaccharide of the Parabacteroides goldsteinii of the present invention to the intestinal tract or to partially or fully colonize to the intestinal tract of subjects.
  • the lipopolysaccharide of the Parabacteroides goldsteinii of the present invention can further use in the preparation of a food, a health food, or a dietary supplement.
  • the invention provides a method of inhibiting an inflammatory response, comprising administering to a subject in need thereof a composition comprising an effective amount of a lipopolysaccharide of a Parabacteroides goldsteinii .
  • a composition comprising an effective amount of a lipopolysaccharide of a Parabacteroides goldsteinii .
  • the sequence position of orthologous genes corresponding to the gene of LpxA, LpxC, LpxD, LpxH, LpxB, LpxK, KdtA, and LpxL to the lipid A known in E. coli could be found, except LpxM.
  • these genes have low identity with E. coli MG1655 strain and Bacteroides dorei DSM17855 strain.
  • the lipopolysaccharide of Parabacteroides goldsteinii of the present invention would not stimulate the secretion of interleukin-1 ⁇ by peripheral blood mononuclear cells, the secretion of TNF- ⁇ by macrophages, and would not induce the Na ⁇ ve B to express surfaces antigen CD86 and to proliferate, which represent the Na ⁇ ve B cells are induced to differentiate, indicating that the lipopolysaccharide of Parabacteroides goldsteinii DSM32939 of the present invention would not cause an immune response in peripheral blood mononuclear cells, macrophages, or B cells, that is, it has low endo-toxicity to individuals.
  • the lipopolysaccharide of Parabacteroides goldsteinii of the present invention can inhibit the immune response induced by the lipopolysaccharide of E. coli in human peripheral blood mononuclear cells, macrophages, or B cells, and has anti-inflammatory activity in peripheral blood mononuclear cells, macrophages, or B cells, and has immunosuppressive ability. Therefore, the lipopolysaccharide of Parabacteroides goldsteinii of the present invention can be used for inhibiting the immune response and the preparation of the compositions thereof, and in particular, it can inhibit the inflammatory response caused by pathogenic lipopolysaccharide.
  • FIG. 1A shows the reaction formula of the biochemical synthesis pathway of Kdo 2 -lipid in E. coli.
  • FIG. 1B shows the BLAST analysis results of the Parabacteroides goldsteinii of one embodiment of the present invention.
  • FIG. 2A shows the line graph of the lipopolysaccharide of the Parabacteroides goldsteinii of one embodiment of the present invention alone not trigger immune response in peripheral blood mononuclear cells.
  • FIG. 2B shows the bar graph of the lipopolysaccharide of the Parabacteroides goldsteinii of one embodiment of the present invention inhibiting inflammatory response of peripheral blood mononuclear cells.
  • FIG. 3A shows the line graph of the lipopolysaccharide of the Parabacteroides goldsteinii of one embodiment of the present invention alone not trigger immune response in macrophages.
  • FIG. 3B shows the bar graph of the lipopolysaccharide of the Parabacteroides goldsteinii of one embodiment of the present invention inhibiting inflammatory response of macrophages. **p ⁇ 0.01.
  • FIG. 4A shows the flow cytometry analysis results of the lipopolysaccharide of the Parabacteroides goldsteinii of one embodiment of the present invention not trigger immune response in B cells.
  • FIG. 4B shows the flow cytometry analysis results of the lipopolysaccharide of the Parabacteroides goldsteinii of one embodiment of the present invention inhibiting inflammatory response of B cells.
  • FIG. 4C shows the bar graph of the lipopolysaccharide of the Parabacteroides goldsteinii of one embodiment of the present invention inhibiting inflammatory response of B cells.
  • the data provides in the present invention represent approximated, experimental values that vary within a range of ⁇ 20%, preferably ⁇ 10%, and most preferably ⁇ 5%.
  • the pharmaceutical composition can be manufactured into a dosage form suitable for parenterally or orally administration using techniques well known to those having skill in the art, including, but not limited to, an injection, for example, sterile aqueous solutions or dispersions, a sterile powder, an external preparation and the like.
  • the pharmaceutical composition could further comprise a pharmaceutically acceptable carrier that is widely used in pharmaceutical manufacturing techniques.
  • the pharmaceutically acceptable carrier can comprise one or more agents selected from the group consisting of a solvent, a buffer, an emulsifier, a suspending agent, a decomposer, a disintegrating agent, a dispersing agent, a binding agent, an excipient, a stabilizing agent, a chelating agent, a diluent, a gelling agent, a preservative, a wetting agent, a lubricant, an absorption delaying agent, a liposome, and the like.
  • the selection and quantity of these reagents falls within the professional literacy and routine skills of those having ordinary skill in the art.
  • the pharmaceutically acceptable carrier comprises a solvent selected from the group consisting of water, normal saline, phosphate buffered saline (PBS), aqueous solution containing alcohol, and combinations thereof.
  • a solvent selected from the group consisting of water, normal saline, phosphate buffered saline (PBS), aqueous solution containing alcohol, and combinations thereof.
  • the pharmaceutical composition can be administered by a parenteral route selected from the group consisting of the intraperitoneal injection, the subcutaneous injection, the intramuscular injection, and the intravenous injection.
  • the “effective amount” describes herein is the amount of the lipopolysaccharide of the Parabacteroides goldsteinii requires for inhibiting the immune response and/or inflammatory response induced by pathogenic lipopolysaccharides in mammalian or human peripheral blood mononuclear cells, macrophages, or B cells, in particular, the immune response and/or inflammatory response induced by lipopolysaccharides of E. coli to inhibit inflammatory responses in mammals or humans.
  • the effective amount varies depending on the species or individual being treated, but the effective amount can be determined experimentally by, for example, a dose escalation test.
  • the operating procedures and parameter conditions for bacterial culture are within the professional literacy and routine techniques of those having ordinary skill in the art.
  • the operating procedures and parameter conditions for culture of peripheral blood mononuclear cells, macrophages, and B cells are within the professional literacy and routine techniques of those having ordinary skill in the art.
  • the operating procedures and parameter conditions for isolation and purification of human peripheral blood mononuclear cells are within the professional literacy and routine techniques of those having ordinary skill in the art.
  • the operating procedures and parameter conditions for isolation and purification of B cells and induction of differentiation of B cell are within the professional literacy and routine techniques of those having ordinary skill in the art.
  • the operating procedures and parameter conditions for purification of lipopolysaccharide are within the professional literacy and routine techniques of those having ordinary skill in the art.
  • the operating procedures and parameter conditions for flow cytometer are within the professional literacy and routine techniques of those having ordinary skill in the art.
  • the “the bacterial component thereof” describes herein is a derivative substance directly or indirectly related to the bacterium when it is cultured, including but not limited to the metabolic product of the bacterium, the structure of the bacterium, the bacteria-related activity and the inactive ingredient, etc.
  • the Parabacteroides goldsteinii ( P. goldsteinii ) strain MTS01 used in the examples of the present invention is a probiotic strain, in particular, the lipopolysaccharides (LPS) of the Parabacteroides goldsteinii can inhibit the inflammatory responses of an individual induced by lipopolysaccharides of Escherichia coli ( E. coli ).
  • the Parabacteroides goldsteinii is deposited in Deutsche Sammlung von Mikroorganismen and Zellkulturen (DSMZ; Inhoffenstr. 7B, D-38124 Braunschweig, Germany) on Oct.
  • the Parabacteroides goldsteinii is an obligate anaerobe that needs to be cultured in an anaerobic incubator at 37° C. for about 48 hours, wherein the culturing system contains 10% CO 2 , 10% H 2 , and 80% N 2 .
  • the liquid culture medium of the Parabacteroides goldsteinii is NIH thioglycollate broth (TGC II) (purchased from BD, USA, No. 225710), and the solid culture medium is Anaerobic blood agar plate (Ana.
  • the Parabacteroides goldsteinii is stored in a ⁇ 80° C. refrigerator for a long-term preservation, and the protective liquid is 25% glycerin. It does not need special cooling treatment and can be stored by freeze drying to stabilize its activity.
  • the lipopolysaccharide of Parabacteroides goldsteinii of the present invention can effectively inhibit the increase in secretion of interleukin-1 ⁇ in peripheral blood mononuclear cells, the increase in secretion of TNF- ⁇ in macrophages, and the increase in expression of surface antigen CD86 and cell proliferation in Na ⁇ ve B cells, indicating that the lipopolysaccharide of Parabacteroides goldsteinii of the present invention can inhibit the immune response induced by the lipopolysaccharide of E.
  • the lipopolysaccharide of Parabacteroides goldsteinii of the present invention can be used for inhibiting the inflammatory response and the preparation of the compositions thereof, and in particular, the lipopolysaccharide of Parabacteroides goldsteinii of the present invention can inhibit the immune response caused by pathogenic lipopolysaccharide.
  • the probiotic or probiotic bacteria is a microorganism, the cells thereof, the mixed strains, the extracts or the metabolites with a positive effect on the host itself, usually derived from the human body and is beneficial to intestinal health.
  • Probiotic or probiotic bacteria can also refer to certain microorganisms that are externally supplemented and are beneficial to the body.
  • the metabolite of the probiotic or probiotic bacteria is a substance which is secreted into the bacterial culture solution after being metabolized by the bacteria, comprising the culture medium for culturing the bacteria.
  • the present invention provides a method of inhibiting an inflammatory response, comprising administering to a subject in need thereof a composition comprising an effective amount of a lipopolysaccharide of a Parabacteroides goldsteinii .
  • the present invention also provides a composition for inhibiting the inflammatory responses, which comprises the lipopolysaccharide of Parabacteroides goldsteinii and a pharmaceutically acceptable carrier, and the composition is a food, a drink, a nutritional supplement, a health care product, or a medicine.
  • Characteristic analysis and comparison of lipopolysaccharides of Parabacteroides goldsteinii of the present invention, methods and steps for isolating and purifying lipopolysaccharides of Parabacteroides goldsteinii , anti-inflammatory activity of lipopolysaccharides of Parabacteroides goldsteinii in peripheral blood mononuclear cells, anti-inflammatory activity of lipopolysaccharides of Parabacteroides goldsteinii in macrophages, and anti-inflammatory activity of lipopolysaccharides of Parabacteroides goldsteinii in B cells will all be described in detail below.
  • the characteristics of the lipopolysaccharides of the Parabacteroides goldsteinii MTS01 was analyzed and compared.
  • Blast Basic Local Alignment Search Tool
  • BLAST is a tool used to find existing sequences that are the same or similar to the sequence to be analyzed, in order to predict its efficacy or role.
  • BLAST is based on KEGG and Search in NCBI-NR's data library.
  • FIG. 1 is the biochemical synthesis pathway of Kdo 2 -lipid A in E. coli , namely the Raetz pathway. As shown in FIG.
  • uridine diphosphate N-acetylglucosamine (UDP-GlcNAc) is as the starting material of the reaction, and a total of seven enzymes LpxA, LpxC, LpxD, LpxH, LpxB, LpxK, and KdtA are used to synthesize the primary product of lipid A of E. coli .
  • the fifth and sixth fluorenyl chains are added to the primary product through two enzymes, LpxL and LpxM, respectively, and lipid A of E. coli is completed, namely Kdo 2 -lipid A in FIG. 1A . It is known that lipid A of E. coli usually contains six fluorenyl chains.
  • Lipopolysaccharides of bacteria are mainly composed of lipid A, core oligo-saccharide, and O poly-saccharide (or O antigen); wherein, lipid A is the main source of toxicity of lipopolysaccharide, and its main function is to assist lipopolysaccharide to fix on the cell membrane of the strain.
  • BLAST analysis was performed on nine genes related to Kdo 2 -lipid A synthesis, i.e. LpxA, LpxC, LpxD, LpxH, LpxB, LpxK, KdtA, LpxL, and LpxM of E. coli.
  • Bacteroides dorei DSM17855 strain belonging to the same genus of Bacteroides related to Kdo2-lipid A synthesis were also subjected to BLAST analysis as the comparison group.
  • FIG. 1B The comparison results of BLAST analysis were shown in FIG. 1B ; wherein, the leftmost column was the putative genes that may be related to the lipid A synthesis in the Parabacteroides goldsteinii MTS01 of the present invention, the middle column was the identity and E value of the putative genes in E. coli MG1655 strain; the rightmost column was the identity and E value of the putative genes in Bacteroides dorei DSM17855 strain. As shown in FIG.
  • the results of the analysis and comparison indicate that in the Parabacteroides goldsteinii MTS01 of the present invention, the sequence position of the ortholog genes corresponding to LpxA, LpxC, LpxD, LpxH, LpxB, LpxK, KdtA, and LpxL could be found in the Parabacteroides goldsteinii MTS01, but the ortholog gene corresponding to LpxM could not be found, and Bacteroides dorei DSM17855 strains had the same analysis results.
  • the lipid A of Parabacteroides goldsteinii and bacteria of the same genus such as Bacteroides thetaiotaomicron, Bacteroides dorei , or Bacteroides fragilis , is all penta-acylated instead of hexa-acylated, as mentioned above, LpxM is an enzyme that adds a sixth fluorenyl chain to lipid A, so the BLAST analysis results was in line with the previous research.
  • the activity test of lipopolysaccharide of Parabacteroides goldsteinii MTS01 to inhibit the inflammatory response of peripheral blood mononuclear cells, PBMC was performed.
  • lipopolysaccharide is located on the cell membrane of bacteria, so the lipopolysaccharide is must first isolated and purified from Parabacteroides goldsteinii MTS01 cells to test the direct effect of lipopolysaccharide on anti-inflammatory response.
  • an RNA isolation reagent i.e. Tri-Reagent
  • Tri-Reagent RNA isolation reagent purification method was used to separate lipopolysaccharide from the entire Parabacteroides goldsteinii MTS01 cell.
  • Parabacteroides goldsteinii MTS01 cells were suspended in a sufficient amount of Tri-Reagent, and then the suspension was subjected under room temperature for fifteen minutes to completely homogenize the cells.
  • 1/10 volume of chloroform was added to the reaction solution to generate a separated phase, and the mixture was vigorously shaken and mixed, and then reacted at room temperature for another ten minutes. The obtained mixture was centrifuged at 12000 g for 10 minutes to separate the aqueous phase and the organic phase.
  • the aqueous phase solution was transferred to a new 1.5 mL centrifuge tube, and distilled water was added to the organic phase. The steps of mixing, shaking for ten minutes, centrifuging, and collecting the aqueous solution were performed twice to ensure that the lipopolysaccharide in the mixture was completely collected.
  • the aqueous phase solutions were combined and vacuum-dried to obtain the crude lipopolysaccharide purified by Tri-Reagent and the crude lipopolysaccharide was dissolved in 0.375 M magnesium chloride (dissolved in 95% ethanol and stored at ⁇ 20° C.).
  • RNA isolation reagents is possible to quickly and easily separate and purify lipopolysaccharide or Lipid A from a small number of bacterial cells. Moreover, this separation and purification method does not require a dedicated separation and purification equipment, and has been used to process a relatively large number of sample purifications.
  • the main functional ingredient in commercial RNA isolation reagents is Tri-Reagent (i.e., Trizol reagent), which is phenol and guanidinium thiocyanate dissolved in aqueous solution.
  • the bacterial cell membrane can be directly destroyed by guanidine thiocyanate in the Tri-Reagent, so there is no need to physically (such as French press) or heat to break the bacterial cell membrane, and the purity of lipopolysaccharide or lipid A purified and isolated by Tri-Reagent is higher than that of conventional means, and the free phosphate pollution in the produced lipopolysaccharide or lipid A product is also lower than that of conventional means.
  • the peripheral blood mononuclear cells used in one embodiment of the present invention were human peripheral blood mononuclear cells (PBMC) isolated from human blood; wherein, the human peripheral blood mononuclear cell line was isolated through a SepMateTM human peripheral blood mononuclear cell isolation tube (purchased from STEMCELL Technologies Inc., Canada), and cultured with 2 ⁇ 10 6 cells per well in a 24-well cultural plate.
  • Human peripheral blood mononuclear cells are composed of lymphocytes, monocytes, and granulocytes.
  • the test was first performed to stimulate peripheral blood mononuclear cells with lipopolysaccharide of Parabacteroides goldsteinii MTS01 alone.
  • Human peripheral blood mononuclear cells were cultured by the above method, and then 0.01 ng/mL, 0.1 ng/mL, 1 ng/mL, 10 ng/mL, 100 ng/mL, 1000 ng/mL, 10000 ng/mL, or 100,000 ng/mL of the aforementioned lipopolysaccharide of Parabacteroides goldsteinii MTS01 of the present invention was respectively added into different wells, and the same concentrations of lipopolysaccharide of E. coli O111:B4 strain were as the negative control groups. After added with the lipopolysaccharide, the human peripheral blood mononuclear cells were incubated at 37° C.
  • E. coli O111:B4 strain was isolated and purified by the same method.
  • E. coli O111:B4 strain is a pathogenic E. coli strain, and its lipopolysaccharide will induce an individual to develop an inflammatory response.
  • FIG. 2A The results of the effect of the lipopolysaccharide of Parabacteroides goldsteinii MTS01 on peripheral blood mononuclear cells alone were shown in FIG. 2A .
  • the amount of interleukin-1 ⁇ secreted by human peripheral blood mononuclear cells was all above 2000 ng/mL, that is, the lipopolysaccharide of pathogenic E.
  • coli could make peripheral blood mononuclear cells secrete cytokines to induce an immune response, indicating that the experimental method could indeed be used to observe the immunomodulatory properties of lipopolysaccharide on peripheral blood mononuclear cells.
  • the amount of interleukin-1 ⁇ secreted by human peripheral blood mononuclear cells were significantly lower than those treated with E. coli O111:B4 strains at each corresponding concentration.
  • the lipopolysaccharide of Parabacteroides goldsteinii MTS01 of the present invention hardly stimulates peripheral blood mononuclear cells to secrete interleukin-1 ⁇ , that is, it does not induce the peripheral blood mononuclear cells to produce an immune response. Therefore, the lipopolysaccharide of Parabacteroides goldsteinii MTS01 of the present invention has low endo-toxicity to individuals.
  • the human peripheral blood mononuclear cells were incubated at 37° C. for 24 hours, and then the same volume of cell culture supernatant from each group was taken out to be analyzed the interleukin-1 ⁇ (IL-1 ⁇ ) by enzyme-linked immunosorbent assay (ELISA).
  • IL-1 ⁇ interleukin-1 ⁇
  • ELISA enzyme-linked immunosorbent assay
  • FIG. 2B The results of the effect of lipopolysaccharides of Parabacteroides goldsteinii MTS01 of the present invention on inhibiting the inflammatory response of peripheral blood mononuclear cells were shown in FIG. 2B .
  • the amount of interleukin-1 ⁇ secreted by human peripheral blood mononuclear cells was significantly lower than that treated with the lipopolysaccharide of E. coli O111: B4 strain alone or the mixed sample of 1:1 volume ratio (ng/mL).
  • the lipopolysaccharide of Parabacteroides goldsteinii MTS01 of the present invention can inhibit the immune response induced by the lipopolysaccharide of E. coli in human peripheral blood mononuclear cells, and therefore has the effect of inhibiting the inflammatory response of peripheral blood mononuclear cells.
  • the activity test of lipopolysaccharide of Parabacteroides goldsteinii MTS01 to inhibit the inflammatory response of macrophages was performed.
  • the macrophages used in the embodiment of the present invention were murine macrophage RAW264.7 cell line.
  • the murine macrophage cell line was purchased from the American Type Culture Collection (ATCC®) and the number is ATCC® TIB-71TM.
  • the macrophages was cultured in DMEM (Dulbecco's Modified Eagle Medium, purchased from Gibco, USA) cell culture medium, containing 10% fetal bovine serum, and 1% antibiotic-antimycotic (purchased from Thermo Fisher Scientific, USA, No. 12100-046), and placed in a 24-well culture plate with 5 ⁇ 10 5 cells per well, and cultured in the 37° C. incubator containing 5% carbon dioxide for 24 hours, so that the macrophages could be attached to the bottom of the culture plate.
  • DMEM Dulbecco's Modified Eagle Medium, purchased
  • the test was first performed to stimulate macrophage with lipopolysaccharide of Parabacteroides goldsteinii MTS01 alone.
  • the murine macrophage cells were cultured by the above method, and then 0.01 ng/mL, 0.1 ng/mL, 1 ng/mL, 10 ng/mL, 100 ng/mL, 1000 ng/mL, or 10000 ng/mL of the aforementioned lipopolysaccharide of Parabacteroides goldsteinii MTS01 of the present invention was respectively added into different wells, and the same concentrations of lipopolysaccharide of E. coli O111:B4 strain were as the negative control groups. After added with the lipopolysaccharide, the murine macrophage cells were incubated at 37° C.
  • tumor necrosis factor- ⁇ TNF- ⁇ or TNF-alpha
  • ELISA tumor necrosis factor- ⁇
  • FIG. 3A The results of the effect of the lipopolysaccharide of Parabacteroides goldsteinii MTS01 on macrophages alone were shown in FIG. 3A .
  • the amount of TNF- ⁇ secreted by murine macrophage cells would increase with increasing concentration, that is, the lipopolysaccharide of pathogenic E. coli could make murine macrophage cells secrete cytokines to induce an immune response, indicating that the experimental method could indeed be used to observe the immunomodulatory properties of lipopolysaccharide on macrophages.
  • the lipopolysaccharide of Parabacteroides goldsteinii MTS01 of the present invention After being treated with lipopolysaccharides of Parabacteroides goldsteinii MTS01 of the present invention with different concentrations alone, the amount of TNF- ⁇ secreted by murine macrophage cells were all approached zero and were significantly lower than those treated with E. coli O111:B4 strains at each corresponding concentration.
  • the results indicate that the lipopolysaccharide of Parabacteroides goldsteinii MTS01 of the present invention would not stimulate macrophages to secrete TNF- ⁇ , that is, it does not induce the macrophages to produce an immune response. Therefore, the lipopolysaccharide of Parabacteroides goldsteinii MTS01 of the present invention has low endo-toxicity to individuals.
  • the test of the anti-inflammatory response effect of lipopolysaccharide of Parabacteroides goldsteinii MTS01 of the present invention on macrophages was further performed.
  • the murine macrophage cells were cultured by the above method, and then lipopolysaccharides of E. coli O111:B4 strain and lipopolysaccharides of Parabacteroides goldsteinii MTS01 of the present invention were added into different wells respectively with 1:0, 1:1, 1:10, 1:100, 1:1000, or 1:10000 volume ratio (ng/mL) of mixed samples.
  • the murine macrophage cells were incubated at 37° C. for 24 hours, and then the same volume of cell culture supernatant from each group was taken out to be analyzed the TNF- ⁇ by ELISA.
  • the analysis results of each group were based on the result from 1 ng/mL of the lipopolysaccharide of E. coli O111: B4 strain. Five replicates were performed in each group and statistical analysis was performed by one-wat ANOVA. The values of each group were expressed as ⁇ standard deviation (*p ⁇ 0.05; **p ⁇ 0.01).
  • FIG. 3B The results of the effect of lipopolysaccharides of Parabacteroides goldsteinii MTS01 of the present invention on inhibiting the inflammatory response of macrophages were shown in FIG. 3B .
  • the amount of TNF- ⁇ secreted by murine macrophage cells was lower than that treated with the lipopolysaccharide of E. coli O111:B4 strain alone (i.e.
  • the lipopolysaccharide of Parabacteroides goldsteinii MTS01 of the present invention has the ability of immunoinhibitory, and is a potential factor for inhibiting the inflammatory response induced by E. coli.
  • the activity test of lipopolysaccharide of Parabacteroides goldsteinii MTS01 to inhibit the inflammatory response of B cells was performed, and the test was performed with Na ⁇ ve B cells.
  • the Na ⁇ ve B cell was isolated and purified from spleen single cells of non-immune-induced mice by EasySepTM mouse B cell isolation kit (purchased from Stemcell Technologies, UK), and the recovery and purity of the isolated Na ⁇ ve B cells were analyzed and confirmed by flow cytometry (FACSAria, BD, USA); wherein, the isolated and 4 ⁇ 10 7 purified Na ⁇ ve B cells were re-suspended in flow cytometry staining buffer (phosphate buffered saline buffer, PBS buffer, containing 0.1 fetal bovine serum), and 5-(and-6)-carboxyfluorescein diacetate succinimidyl ester, CFDA-SE (purchased from Molecular Probes, USA) was used for Na ⁇ ve B cell stain
  • the Na ⁇ ve B cells were immediately washed three times with cold flow cytometry staining buffer, and then the Na ⁇ ve B cells were re-suspended in the cell culture medium, and were then cultured in a 24-well culture plate at a concentration of 2 ⁇ 10 6 cells/mL per well.
  • CFDA-SE is frequently used in cell proliferation assays, as it is partitioned approximately equally between the progeny so that cell division can be followed as a successive halving of the fluorescence intensity through multiple generational divisions; therefore, the B cell proliferation stimulated with various lipopolysaccharides doses was analyzed by flow cytometry.
  • the Na ⁇ ve B cells are induced by lipopolysaccharide to induce the Na ⁇ ve B cells to perform an immune response of antigen presentation.
  • CD86 and CD19 are B-cell-specific antigen-presenting proteins, and CD86 is only expressed after the Na ⁇ ve B cell differentiation. Therefore, if the Na ⁇ ve B cell produces an immune response, the expression of the surface antigens of CD86 and the cell proliferation would increase, and it would promote the differentiation of the Na ⁇ veB cell into plasma cells, which are the main cells that secrete antibodies and are larger than the Na ⁇ ve B cells. In addition, if B cells produce an immune response, it would also increase the secretion of TNF- ⁇ .
  • the test was first performed to stimulate B cells with lipopolysaccharide of Parabacteroides goldsteinii MTS01 alone. After the Na ⁇ ve B cells were isolated and purified by the above method, the 100 ng/mL, 1000 ng/mL, or 10000 ng/mL of the aforementioned lipopolysaccharide of Parabacteroides goldsteinii MTS01 of the present invention was respectively added into different wells, and the 100 ng/mL, 1000 ng/mL, or 10000 ng/mL of lipopolysaccharide of E.
  • coli O111:B4 strain were as the negative control groups. After added with the lipopolysaccharide, the B cells were incubated at 37° C. for 48 hours, flow cytometry was used to analyze the size and the expression of surface antigens of CD86 and proliferation of B cells after immune induction. At the same time, the same volume of cell culture supernatant from each group was taken out to be analyzed the TNF- ⁇ secreted from B cells.
  • FIGS. 4A to 4C The results of the effect of the lipopolysaccharide of Parabacteroides goldsteinii MTS01 on B cells alone were shown in FIGS. 4A to 4C .
  • FIG. 4A after being treated with 100 ng/mL, 1000 ng/mL, and 10000 ng/mL of the lipopolysaccharides of E. coli O111:B4 strains alone, the size and the expression of surface antigens of CD86 and proliferation of B cells would increase with increasing concentration.
  • FIGS. 4B and 4C after being treated with 1000 ng/mL of the lipopolysaccharides of E.
  • the test of the anti-inflammatory response effect of lipopolysaccharide of Parabacteroides goldsteinii MTS01 of the present invention on B cells was further performed.
  • the lipopolysaccharides of E. coli O111:B4 strain and lipopolysaccharides of Parabacteroides goldsteinii MTS01 of the present invention were added into different wells respectively with 1000:1000, or 1000:10000 volume ratio (ng/mL) of mixed samples.
  • the B cells were incubated at 37° C. for 48 hours, the same volume of cell culture supernatant from each group was taken out to be analyzed the TNF- ⁇ secreted from B cells.
  • flow cytometry was used to analyze the expression of surface antigen CD86 and cell proliferation of B cells after immune induction.
  • FIGS. 4B and 4C The results of the effect of lipopolysaccharides of Parabacteroides goldsteinii MTS01 of the present invention on inhibiting the inflammatory response of B cells were shown in FIGS. 4B and 4C .
  • FIGS. 4B and 4C after being treated with the mixed samples of 1000:1000 or 1000:10000 volume ratios (ng/mL), respectively, 41.7% or 62.4% of B cells expressed surface antigen of CD86 protein, and, respectively, 18.6% or 30.4% of B cells were proliferative, and the amount of TNF- ⁇ secreted by B cells was respectively about 20 ng/mL or 36 ng/mL; wherein, the inhibition effect of the mixed samples of 1000:1000 volume ratios (ng/mL) was better than that of the mixed samples of 1000:10000 volume ratios (ng/mL).
  • the use of the lipopolysaccharide of the Parabacteroides goldsteinii of the present invention in the inhibition of inflammatory response can be, but is not limited to, oral administration to the subject in need thereof.
  • the composition can be orally administered along with food; therefore, the preparation of the composition comprising the Parabacteroides goldsteinii of the present invention can further include a protein, a monosaccharide, a disaccharide, an oligosaccharide, an oligosaccharide, a polysaccharide, a carbohydrate, an amino acid, a lipid, a vitamin, or any combination thereof, and the composition further comprises a pharmaceutically acceptable excipient, carrier, adjuvant, and/or food additive.
  • the preparation of the composition comprising the lipopolysaccharide of the Parabacteroides goldsteinii of the present invention can further comprise a pharmaceutically acceptable carrier or another adjuvant well-known in the art.
  • the composition is in the form of, but is not limited to, a spray gas, a solution, a semi-solid, a solid, a gelatin capsule, a soft capsule, a tablet, an oral strip, a chewing gum, and/or a freeze-dried powder in order to deliver the lipopolysaccharide of the Parabacteroides goldsteinii of the present invention to the intestinal tract or to partially or fully colonize to the intestinal tract of subjects.
  • the lipopolysaccharide of the Parabacteroides goldsteinii of the present invention can further use in the preparation of a food, a health food, or a dietary supplement.
  • the invention provides a method of inhibiting an inflammatory response, comprising administering to a subject in need thereof a composition comprising an effective amount of a lipopolysaccharide of a Parabacteroides goldsteinii .
  • a composition comprising an effective amount of a lipopolysaccharide of a Parabacteroides goldsteinii .
  • the sequence position of orthologous genes corresponding to the gene of LpxA, LpxC, LpxD, LpxH, LpxB, LpxK, KdtA, and LpxL, to the lipid A known in E. coli could be found, except LpxM.
  • these genes have low identity with E. coli MG1655 strain and Bacteroides dorei DSM17855 strain.
  • the lipopolysaccharide of Parabacteroides goldsteinii of the present invention would not stimulate the secretion of interleukin-1 ⁇ by peripheral blood mononuclear cells, the secretion of TNF- ⁇ by macrophages, and would not induce the Na ⁇ ve B to express surfaces antigen CD86 and proliferation, which represent the Na ⁇ ve B cells are induced to differentiate, indicating that the lipopolysaccharide of Parabacteroides goldsteinii MTS01 of the present invention would not cause an immune response in peripheral blood mononuclear cells, macrophages, or B cells, that is, it has low endo-toxicity to individuals.
  • the lipopolysaccharide of Parabacteroides goldsteinii of the present invention can inhibit the immune response induced by the lipopolysaccharide of E. coli in human peripheral blood mononuclear cells, macrophages, or B cells, and has anti-inflammatory activity in peripheral blood mononuclear cells, macrophages, or B cells, and has immunosuppressive ability. Therefore, the lipopolysaccharide of Parabacteroides goldsteinii of the present invention can be used for inhibiting the immune response and the preparation of the compositions thereof, and in particular, it can inhibit the inflammatory response caused by pathogenic lipopolysaccharide.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The present invention describes a method of inhibiting inflammatory response by using a lipopolysaccharide of Parabacteroides goldsteinii. The lipopolysaccharide of Parabacteroides goldsteinii can effectively inhibit the immune responses caused by pathogenic lipopolysaccharides in peripheral blood mononuclear cells, macrophages, and/or B cells, and then can be effectively used to inhibit the inflammatory responses and the preparation of the related compositions.

Description

CROSS-REFERENCE TO RELATED APPLICATION
This application claims priority of U.S. provisional application No. 62/796,599, filed on Jan. 25, 2019, and priority of Taiwan patent application No. 108148713, filed on Dec. 31, 2019 the content of which are incorporated herein in its entirety by reference.
BACKGROUND OF THE INVENTION 1. Field of the Invention
The present invention relates to a method of using a lipopolysaccharide of Parabacteroides goldsteinii, in particular to the use of the lipopolysaccharide of Parabacteroides goldsteinii to inhibit inflammatory response; wherein, the lipopolysaccharide of Parabacteroides goldsteinii can effectively inhibit the immune response of peripheral blood mononuclear cells, macrophages and/or B cells to effectively inhibit the occurrence of inflammatory response.
2. The Prior Art
Inflammatory response is a defensive response of vascular system tissues to inflammatory factors and local damage. It is mainly a physiological response triggered by stimuli such as trauma, bleeding or pathogen infection, including symptoms of redness, swelling, fever, pain, etc. Inflammatory response is a protective measure of the innate immune system to remove harmful stimuli or pathogens and promote tissue repair. Usually, the inflammatory response is beneficial.
Lipopolysaccharide (LPS) is one of the main components on the cell membrane of Gram-negative bacteria, and it is also a marker of bacterial invasion, and it is an endotoxin. LPS mainly provides and maintains the structural integrity of bacteria, and protects the cell membrane of bacteria from attack by certain chemicals, such as the immune response from the host. When a microorganism invades an individual and releases a large amount of lipopolysaccharide, it stimulates immune cells to secrete a large number of cytokine that promote inflammatory response, such as tumor necrosis factor-α (TNF-α), interleukin-1 (Interleukin-1, IL-1), etc., and cause individuals to produce excessive inflammatory response, and even lead to the occurrence of sepsis, the most serious may be fatal, and the biological response induced by lipopolysaccharide is considered to be the main cause of sepsis.
However, about 110,000 people still suffer from sepsis every year in Taiwan, with an average of 300 new cases every day. As the elderly population grows, the number of immunosuppressed patients increases, the number of invasive treatment tests increases, and microbial resistance increases, the number of cases of sepsis is currently on the rise, and despite the development of medicine so far, the mortality rate of severe sepsis is still as high as 30 to 40 percent.
Therefore, to sum up, in response to the high incidence and mortality of sepsis and based on the improvement of modern living standards and the improvement of the concept of health care, it is really necessary to develop a composition that is convenient and effective in the front-end to slow down the immune response or to suppress the inflammatory response caused by pathogens.
SUMMARY OF THE INVENTION
One objective of the present invention is to provide a method of inhibiting an inflammatory response, comprising administering to a subject in need thereof a composition comprising an effective amount of a lipopolysaccharide of a Parabacteroides goldsteinii.
In one embodiment of the present invention, the lipopolysaccharide of the Parabacteroides goldsteinii inhibits an immune response of a peripheral blood mononuclear cell and inhibits the peripheral blood mononuclear cell secretes a cytokine.
In one embodiment of the present invention, the lipopolysaccharide of the Parabacteroides goldsteinii inhibits an immune response of a macrophage and inhibits the macrophage secretes a cytokine.
In one embodiment of the present invention, the lipopolysaccharide of the Parabacteroides goldsteinii inhibits an immune response of a B cell and inhibits the B cell differentiates or secretes a cytokine.
In one embodiment of the present invention, the inflammatory response is induced by a pathogenic lipopolysaccharide, and the pathogenic lipopolysaccharide is from an Escherichia coli.
In one embodiment of the present invention, the Parabacteroides goldsteinii is Parabacteroides goldsteinii DSM32939.
The use of the lipopolysaccharide of the Parabacteroides goldsteinii of the present invention in the inhibition of inflammatory response can be, but is not limited to, oral administration to the subject in need thereof. The composition can be orally administered along with food; therefore, the preparation of the composition comprising the Parabacteroides goldsteinii of the present invention can further include a protein, a monosaccharide, a disaccharide, an oligosaccharide, an oligosaccharide, a polysaccharide, a carbohydrate, an amino acid, a lipid, a vitamin, or any combination thereof, and the composition further comprises a pharmaceutically acceptable excipient, carrier, adjuvant, and/or food additive.
Otherwise, the preparation of the composition comprising the lipopolysaccharide of the Parabacteroides goldsteinii of the present invention can further comprise a pharmaceutically acceptable carrier or another adjuvant well-known in the art. The composition is in the form of, but is not limited to, a spray gas, a solution, a semi-solid, a solid, a gelatin capsule, a soft capsule, a tablet, an oral strip, a chewing gum, and/or a freeze-dried powder in order to deliver the lipopolysaccharide of the Parabacteroides goldsteinii of the present invention to the intestinal tract or to partially or fully colonize to the intestinal tract of subjects. Simultaneously, the lipopolysaccharide of the Parabacteroides goldsteinii of the present invention can further use in the preparation of a food, a health food, or a dietary supplement.
The invention provides a method of inhibiting an inflammatory response, comprising administering to a subject in need thereof a composition comprising an effective amount of a lipopolysaccharide of a Parabacteroides goldsteinii. In the Parabacteroides goldsteinii of the present invention, the sequence position of orthologous gens corresponding to the gene of LpxA, LpxC, LpxD, LpxH, LpxB, LpxK, KdtA, and LpxL to the lipid A known in E. coli could be found, except LpxM. However, these genes have low identity with E. coli MG1655 strain and Bacteroides dorei DSM17855 strain. The lipopolysaccharide of Parabacteroides goldsteinii of the present invention would not stimulate the secretion of interleukin-1β by peripheral blood mononuclear cells, the secretion of TNF-α by macrophages, and would not induce the Naïve B to express surfaces antigen CD86 and to proliferate, which represent the Naïve B cells are induced to differentiate, indicating that the lipopolysaccharide of Parabacteroides goldsteinii DSM32939 of the present invention would not cause an immune response in peripheral blood mononuclear cells, macrophages, or B cells, that is, it has low endo-toxicity to individuals. Furthermore, the lipopolysaccharide of Parabacteroides goldsteinii of the present invention can inhibit the immune response induced by the lipopolysaccharide of E. coli in human peripheral blood mononuclear cells, macrophages, or B cells, and has anti-inflammatory activity in peripheral blood mononuclear cells, macrophages, or B cells, and has immunosuppressive ability. Therefore, the lipopolysaccharide of Parabacteroides goldsteinii of the present invention can be used for inhibiting the immune response and the preparation of the compositions thereof, and in particular, it can inhibit the inflammatory response caused by pathogenic lipopolysaccharide.
The embodiments of the present invention are further described with the following drawings. The following embodiments are given to illustrate the present invention and are not intended to limit the scope of the present invention, and those having ordinary skill in the art can make some modifications and refinements without departing from the spirit and scope of the present invention. Therefore, the scope of the present invention is defined by the scope of the appended claims.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1A shows the reaction formula of the biochemical synthesis pathway of Kdo2-lipid in E. coli.
FIG. 1B shows the BLAST analysis results of the Parabacteroides goldsteinii of one embodiment of the present invention.
FIG. 2A shows the line graph of the lipopolysaccharide of the Parabacteroides goldsteinii of one embodiment of the present invention alone not trigger immune response in peripheral blood mononuclear cells.
FIG. 2B shows the bar graph of the lipopolysaccharide of the Parabacteroides goldsteinii of one embodiment of the present invention inhibiting inflammatory response of peripheral blood mononuclear cells.
FIG. 3A shows the line graph of the lipopolysaccharide of the Parabacteroides goldsteinii of one embodiment of the present invention alone not trigger immune response in macrophages.
FIG. 3B shows the bar graph of the lipopolysaccharide of the Parabacteroides goldsteinii of one embodiment of the present invention inhibiting inflammatory response of macrophages. **p<0.01.
FIG. 4A shows the flow cytometry analysis results of the lipopolysaccharide of the Parabacteroides goldsteinii of one embodiment of the present invention not trigger immune response in B cells.
FIG. 4B shows the flow cytometry analysis results of the lipopolysaccharide of the Parabacteroides goldsteinii of one embodiment of the present invention inhibiting inflammatory response of B cells.
FIG. 4C shows the bar graph of the lipopolysaccharide of the Parabacteroides goldsteinii of one embodiment of the present invention inhibiting inflammatory response of B cells.
 DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT
Statistical analysis is performed by Excel software. Data are expressed as mean±standard deviation (SD), and differences between groups are statistically analyzed by one-way ANOVA.
The data provides in the present invention represent approximated, experimental values that vary within a range of ±20%, preferably ±10%, and most preferably ±5%.
According to the present invention, the pharmaceutical composition can be manufactured into a dosage form suitable for parenterally or orally administration using techniques well known to those having skill in the art, including, but not limited to, an injection, for example, sterile aqueous solutions or dispersions, a sterile powder, an external preparation and the like.
According to the present invention, the pharmaceutical composition could further comprise a pharmaceutically acceptable carrier that is widely used in pharmaceutical manufacturing techniques. For example, the pharmaceutically acceptable carrier can comprise one or more agents selected from the group consisting of a solvent, a buffer, an emulsifier, a suspending agent, a decomposer, a disintegrating agent, a dispersing agent, a binding agent, an excipient, a stabilizing agent, a chelating agent, a diluent, a gelling agent, a preservative, a wetting agent, a lubricant, an absorption delaying agent, a liposome, and the like. The selection and quantity of these reagents falls within the professional literacy and routine skills of those having ordinary skill in the art.
According to the present invention, the pharmaceutically acceptable carrier comprises a solvent selected from the group consisting of water, normal saline, phosphate buffered saline (PBS), aqueous solution containing alcohol, and combinations thereof.
According to the present invention, the pharmaceutical composition can be administered by a parenteral route selected from the group consisting of the intraperitoneal injection, the subcutaneous injection, the intramuscular injection, and the intravenous injection.
Definition
The “effective amount” describes herein is the amount of the lipopolysaccharide of the Parabacteroides goldsteinii requires for inhibiting the immune response and/or inflammatory response induced by pathogenic lipopolysaccharides in mammalian or human peripheral blood mononuclear cells, macrophages, or B cells, in particular, the immune response and/or inflammatory response induced by lipopolysaccharides of E. coli to inhibit inflammatory responses in mammals or humans. The effective amount varies depending on the species or individual being treated, but the effective amount can be determined experimentally by, for example, a dose escalation test.
According to the present invention, the operating procedures and parameter conditions for bacterial culture are within the professional literacy and routine techniques of those having ordinary skill in the art.
According to the present invention, the operating procedures and parameter conditions for culture of peripheral blood mononuclear cells, macrophages, and B cells are within the professional literacy and routine techniques of those having ordinary skill in the art.
According to the present invention, the operating procedures and parameter conditions for isolation and purification of human peripheral blood mononuclear cells are within the professional literacy and routine techniques of those having ordinary skill in the art.
According to the present invention, the operating procedures and parameter conditions for isolation and purification of B cells and induction of differentiation of B cell are within the professional literacy and routine techniques of those having ordinary skill in the art.
According to the present invention, the operating procedures and parameter conditions for purification of lipopolysaccharide are within the professional literacy and routine techniques of those having ordinary skill in the art.
According to the present invention, the operating procedures and parameter conditions for flow cytometer are within the professional literacy and routine techniques of those having ordinary skill in the art.
The “the bacterial component thereof” describes herein is a derivative substance directly or indirectly related to the bacterium when it is cultured, including but not limited to the metabolic product of the bacterium, the structure of the bacterium, the bacteria-related activity and the inactive ingredient, etc.
The Strain of the Parabacteroides goldsteinii of the Present Invention
The Parabacteroides goldsteinii (P. goldsteinii) strain MTS01 used in the examples of the present invention is a probiotic strain, in particular, the lipopolysaccharides (LPS) of the Parabacteroides goldsteinii can inhibit the inflammatory responses of an individual induced by lipopolysaccharides of Escherichia coli (E. coli). The Parabacteroides goldsteinii is deposited in Deutsche Sammlung von Mikroorganismen and Zellkulturen (DSMZ; Inhoffenstr. 7B, D-38124 Braunschweig, Germany) on Oct. 29, 2018, and the number is DSM 32939; the Parabacteroides goldsteinii is also deposited in the Food Industry Research and Development Institute (Taiwan) on Feb. 15, 2019, and the number is BCRC910869. The Parabacteroides goldsteinii is an obligate anaerobe that needs to be cultured in an anaerobic incubator at 37° C. for about 48 hours, wherein the culturing system contains 10% CO2, 10% H2, and 80% N2. The liquid culture medium of the Parabacteroides goldsteinii is NIH thioglycollate broth (TGC II) (purchased from BD, USA, No. 225710), and the solid culture medium is Anaerobic blood agar plate (Ana. BAP) (purchased from CREATIVE LIFESCIENCES, Taiwan). The Parabacteroides goldsteinii is stored in a −80° C. refrigerator for a long-term preservation, and the protective liquid is 25% glycerin. It does not need special cooling treatment and can be stored by freeze drying to stabilize its activity.
In the examples of the present invention, it was confirmed through cell experiments that the lipopolysaccharide of Parabacteroides goldsteinii of the present invention can effectively inhibit the increase in secretion of interleukin-1β in peripheral blood mononuclear cells, the increase in secretion of TNF-α in macrophages, and the increase in expression of surface antigen CD86 and cell proliferation in Naïve B cells, indicating that the lipopolysaccharide of Parabacteroides goldsteinii of the present invention can inhibit the immune response induced by the lipopolysaccharide of E. coli in human peripheral blood mononuclear cells, macrophages, or B cells, and has immunosuppressive ability; therefore, the lipopolysaccharide of Parabacteroides goldsteinii of the present invention can be used for inhibiting the inflammatory response and the preparation of the compositions thereof, and in particular, the lipopolysaccharide of Parabacteroides goldsteinii of the present invention can inhibit the immune response caused by pathogenic lipopolysaccharide.
According to the present invention, the probiotic or probiotic bacteria is a microorganism, the cells thereof, the mixed strains, the extracts or the metabolites with a positive effect on the host itself, usually derived from the human body and is beneficial to intestinal health. Probiotic or probiotic bacteria can also refer to certain microorganisms that are externally supplemented and are beneficial to the body. Wherein, the metabolite of the probiotic or probiotic bacteria is a substance which is secreted into the bacterial culture solution after being metabolized by the bacteria, comprising the culture medium for culturing the bacteria.
The present invention provides a method of inhibiting an inflammatory response, comprising administering to a subject in need thereof a composition comprising an effective amount of a lipopolysaccharide of a Parabacteroides goldsteinii. At the same time, the present invention also provides a composition for inhibiting the inflammatory responses, which comprises the lipopolysaccharide of Parabacteroides goldsteinii and a pharmaceutically acceptable carrier, and the composition is a food, a drink, a nutritional supplement, a health care product, or a medicine.
Characteristic analysis and comparison of lipopolysaccharides of Parabacteroides goldsteinii of the present invention, methods and steps for isolating and purifying lipopolysaccharides of Parabacteroides goldsteinii, anti-inflammatory activity of lipopolysaccharides of Parabacteroides goldsteinii in peripheral blood mononuclear cells, anti-inflammatory activity of lipopolysaccharides of Parabacteroides goldsteinii in macrophages, and anti-inflammatory activity of lipopolysaccharides of Parabacteroides goldsteinii in B cells will all be described in detail below.
Example 1
Characteristic Analysis and Comparison of Lipopolysaccharides of Parabacteroides goldsteinii
In one embodiment of the present invention, the characteristics of the lipopolysaccharides of the Parabacteroides goldsteinii MTS01 was analyzed and compared. First, perform a BLAST search of the entire genome of the Parabacteroides goldsteinii to identify candidate genes responsible for biosynthetic lipid A; wherein, Blast (Basic Local Alignment Search Tool) is an algorithm used to compare the primary structure of biological sequences (such as the amino acid sequences of different proteins or the DNA sequences of different genes). By comparing with information in a database known to contain several sequences, BLAST is a tool used to find existing sequences that are the same or similar to the sequence to be analyzed, in order to predict its efficacy or role. BLAST is based on KEGG and Search in NCBI-NR's data library.
In this embodiment, the BLAST search was based on E. coli MG1655 strain (Genome accession number: U00096) and commercial Bacteroides dorei (B. dorei) DSM17855 strain, and relevant genes responsible for biosynthetic lipid A were used as a reference point for comparison; wherein, FIG. 1 is the biochemical synthesis pathway of Kdo2-lipid A in E. coli, namely the Raetz pathway. As shown in FIG. 1A, uridine diphosphate N-acetylglucosamine (UDP-GlcNAc) is as the starting material of the reaction, and a total of seven enzymes LpxA, LpxC, LpxD, LpxH, LpxB, LpxK, and KdtA are used to synthesize the primary product of lipid A of E. coli. The fifth and sixth fluorenyl chains are added to the primary product through two enzymes, LpxL and LpxM, respectively, and lipid A of E. coli is completed, namely Kdo2-lipid A in FIG. 1A. It is known that lipid A of E. coli usually contains six fluorenyl chains. Lipopolysaccharides of bacteria are mainly composed of lipid A, core oligo-saccharide, and O poly-saccharide (or O antigen); wherein, lipid A is the main source of toxicity of lipopolysaccharide, and its main function is to assist lipopolysaccharide to fix on the cell membrane of the strain.
Therefore, BLAST analysis was performed on nine genes related to Kdo2-lipid A synthesis, i.e. LpxA, LpxC, LpxD, LpxH, LpxB, LpxK, KdtA, LpxL, and LpxM of E. coli. Bacteroides dorei DSM17855 strain belonging to the same genus of Bacteroides related to Kdo2-lipid A synthesis were also subjected to BLAST analysis as the comparison group.
The comparison results of BLAST analysis were shown in FIG. 1B; wherein, the leftmost column was the putative genes that may be related to the lipid A synthesis in the Parabacteroides goldsteinii MTS01 of the present invention, the middle column was the identity and E value of the putative genes in E. coli MG1655 strain; the rightmost column was the identity and E value of the putative genes in Bacteroides dorei DSM17855 strain. As shown in FIG. 1B, the results of the analysis and comparison indicate that in the Parabacteroides goldsteinii MTS01 of the present invention, the sequence position of the ortholog genes corresponding to LpxA, LpxC, LpxD, LpxH, LpxB, LpxK, KdtA, and LpxL could be found in the Parabacteroides goldsteinii MTS01, but the ortholog gene corresponding to LpxM could not be found, and Bacteroides dorei DSM17855 strains had the same analysis results. According to previous research, the lipid A of Parabacteroides goldsteinii and bacteria of the same genus, such as Bacteroides thetaiotaomicron, Bacteroides dorei, or Bacteroides fragilis, is all penta-acylated instead of hexa-acylated, as mentioned above, LpxM is an enzyme that adds a sixth fluorenyl chain to lipid A, so the BLAST analysis results was in line with the previous research.
It can also be known from the previous research that there is heterogeneity between the lipopolysaccharides of different genus form Bacteroides, and as shown in FIG. 1B, the identity of the eight corresponding orthologous genes in the Parabacteroides goldsteinii MTS01 of the present invention and the Bacteroides dorei DSM17855 strain of the same genus was not high, therefore the results of the BLAST analysis are also consistent with the previous study.
Example 2
Effect of Parabacteroides goldsteinii on Inhibiting Inflammatory Response of Peripheral Blood Mononuclear Cell
In one embodiment of the present invention, the activity test of lipopolysaccharide of Parabacteroides goldsteinii MTS01 to inhibit the inflammatory response of peripheral blood mononuclear cells, PBMC, was performed. However, lipopolysaccharide is located on the cell membrane of bacteria, so the lipopolysaccharide is must first isolated and purified from Parabacteroides goldsteinii MTS01 cells to test the direct effect of lipopolysaccharide on anti-inflammatory response.
In the embodiment of the present invention, an RNA isolation reagent (i.e. Tri-Reagent) purification method was used to separate lipopolysaccharide from the entire Parabacteroides goldsteinii MTS01 cell. First, Parabacteroides goldsteinii MTS01 cells were suspended in a sufficient amount of Tri-Reagent, and then the suspension was subjected under room temperature for fifteen minutes to completely homogenize the cells. Next, 1/10 volume of chloroform was added to the reaction solution to generate a separated phase, and the mixture was vigorously shaken and mixed, and then reacted at room temperature for another ten minutes. The obtained mixture was centrifuged at 12000 g for 10 minutes to separate the aqueous phase and the organic phase. The aqueous phase solution was transferred to a new 1.5 mL centrifuge tube, and distilled water was added to the organic phase. The steps of mixing, shaking for ten minutes, centrifuging, and collecting the aqueous solution were performed twice to ensure that the lipopolysaccharide in the mixture was completely collected. The aqueous phase solutions were combined and vacuum-dried to obtain the crude lipopolysaccharide purified by Tri-Reagent and the crude lipopolysaccharide was dissolved in 0.375 M magnesium chloride (dissolved in 95% ethanol and stored at −20° C.). Then, after centrifugation at 12000 g for 15 minutes, the supernatant was removed, and the pellet was re-suspended in distilled water and freeze-dried to obtain a fluffy white solid, which is the lipopolysaccharide of Parabacteroides goldsteinii MTS01 of the present invention.
The commercial RNA isolation reagents is possible to quickly and easily separate and purify lipopolysaccharide or Lipid A from a small number of bacterial cells. Moreover, this separation and purification method does not require a dedicated separation and purification equipment, and has been used to process a relatively large number of sample purifications. The main functional ingredient in commercial RNA isolation reagents is Tri-Reagent (i.e., Trizol reagent), which is phenol and guanidinium thiocyanate dissolved in aqueous solution. The bacterial cell membrane can be directly destroyed by guanidine thiocyanate in the Tri-Reagent, so there is no need to physically (such as French press) or heat to break the bacterial cell membrane, and the purity of lipopolysaccharide or lipid A purified and isolated by Tri-Reagent is higher than that of conventional means, and the free phosphate pollution in the produced lipopolysaccharide or lipid A product is also lower than that of conventional means.
The peripheral blood mononuclear cells used in one embodiment of the present invention were human peripheral blood mononuclear cells (PBMC) isolated from human blood; wherein, the human peripheral blood mononuclear cell line was isolated through a SepMate™ human peripheral blood mononuclear cell isolation tube (purchased from STEMCELL Technologies Inc., Canada), and cultured with 2×106 cells per well in a 24-well cultural plate. Human peripheral blood mononuclear cells are composed of lymphocytes, monocytes, and granulocytes.
In order to preliminary understand the immunoregulatory properties of lipopolysaccharide of Parabacteroides goldsteinii MTS01 of the present invention on peripheral blood mononuclear cells, the test was first performed to stimulate peripheral blood mononuclear cells with lipopolysaccharide of Parabacteroides goldsteinii MTS01 alone. Human peripheral blood mononuclear cells were cultured by the above method, and then 0.01 ng/mL, 0.1 ng/mL, 1 ng/mL, 10 ng/mL, 100 ng/mL, 1000 ng/mL, 10000 ng/mL, or 100,000 ng/mL of the aforementioned lipopolysaccharide of Parabacteroides goldsteinii MTS01 of the present invention was respectively added into different wells, and the same concentrations of lipopolysaccharide of E. coli O111:B4 strain were as the negative control groups. After added with the lipopolysaccharide, the human peripheral blood mononuclear cells were incubated at 37° C. for 24 hours, and then the same volume of cell culture supernatant from each group was taken out to be analyzed the interleukin-1β (IL-1β) by enzyme-linked immunosorbent assay (ELISA). Wherein, the lipopolysaccharide of E. coli O111:B4 strain (purchased from Sigma, USA) was isolated and purified by the same method. E. coli O111:B4 strain is a pathogenic E. coli strain, and its lipopolysaccharide will induce an individual to develop an inflammatory response.
The results of the effect of the lipopolysaccharide of Parabacteroides goldsteinii MTS01 on peripheral blood mononuclear cells alone were shown in FIG. 2A. As shown in FIG. 2A, after being treated with lipopolysaccharides of E. coli O111:B4 strains with different concentrations alone, the amount of interleukin-1β secreted by human peripheral blood mononuclear cells was all above 2000 ng/mL, that is, the lipopolysaccharide of pathogenic E. coli could make peripheral blood mononuclear cells secrete cytokines to induce an immune response, indicating that the experimental method could indeed be used to observe the immunomodulatory properties of lipopolysaccharide on peripheral blood mononuclear cells. After being treated with lipopolysaccharides of Parabacteroides goldsteinii MTS01 of the present invention with different concentrations alone, the amount of interleukin-1β secreted by human peripheral blood mononuclear cells were significantly lower than those treated with E. coli O111:B4 strains at each corresponding concentration. The results indicate that the lipopolysaccharide of Parabacteroides goldsteinii MTS01 of the present invention hardly stimulates peripheral blood mononuclear cells to secrete interleukin-1β, that is, it does not induce the peripheral blood mononuclear cells to produce an immune response. Therefore, the lipopolysaccharide of Parabacteroides goldsteinii MTS01 of the present invention has low endo-toxicity to individuals.
Next, in order to better understand the immunoregulatory characteristics of lipopolysaccharide of Parabacteroides goldsteinii MTS01 of the present invention on peripheral blood mononuclear cells, the test of the anti-inflammatory response effect of lipopolysaccharide of Parabacteroides goldsteinii MTS01 of the present invention on peripheral blood mononuclear cells was further performed. First, human peripheral blood mononuclear cells were cultured by the above method, and then lipopolysaccharides of E. coli O111:B4 strain and lipopolysaccharides of Parabacteroides goldsteinii MTS01 of the present invention were added into different wells respectively with 1:0, 1:1, 1:10, or 1:100 volume ratio (ng/mL) of mixed samples. After added with the lipopolysaccharide, the human peripheral blood mononuclear cells were incubated at 37° C. for 24 hours, and then the same volume of cell culture supernatant from each group was taken out to be analyzed the interleukin-1β (IL-1β) by enzyme-linked immunosorbent assay (ELISA). Wherein, the analysis results of each group were based on the result from 0.1 ng/mL of the lipopolysaccharide of E. coli O111: B4 strain.
The results of the effect of lipopolysaccharides of Parabacteroides goldsteinii MTS01 of the present invention on inhibiting the inflammatory response of peripheral blood mononuclear cells were shown in FIG. 2B. As shown in FIG. 2B, after being treated with the mixed samples of 1:10 or 1:100 volume ratios (ng/mL), the amount of interleukin-1β secreted by human peripheral blood mononuclear cells was significantly lower than that treated with the lipopolysaccharide of E. coli O111: B4 strain alone or the mixed sample of 1:1 volume ratio (ng/mL). The results indicate that the lipopolysaccharide of Parabacteroides goldsteinii MTS01 of the present invention can inhibit the immune response induced by the lipopolysaccharide of E. coli in human peripheral blood mononuclear cells, and therefore has the effect of inhibiting the inflammatory response of peripheral blood mononuclear cells.
Example 3
Effect of Parabacteroides goldsteinii on Inhibiting Inflammatory Response of Macrophage
In the embodiment of the present invention, the activity test of lipopolysaccharide of Parabacteroides goldsteinii MTS01 to inhibit the inflammatory response of macrophages was performed. Wherein, the macrophages used in the embodiment of the present invention were murine macrophage RAW264.7 cell line. The murine macrophage cell line was purchased from the American Type Culture Collection (ATCC®) and the number is ATCC® TIB-71™. The macrophages was cultured in DMEM (Dulbecco's Modified Eagle Medium, purchased from Gibco, USA) cell culture medium, containing 10% fetal bovine serum, and 1% antibiotic-antimycotic (purchased from Thermo Fisher Scientific, USA, No. 12100-046), and placed in a 24-well culture plate with 5×105 cells per well, and cultured in the 37° C. incubator containing 5% carbon dioxide for 24 hours, so that the macrophages could be attached to the bottom of the culture plate.
In order to preliminary understand the immunoregulatory properties of lipopolysaccharide of Parabacteroides goldsteinii MTS01 of the present invention on macrophages, the test was first performed to stimulate macrophage with lipopolysaccharide of Parabacteroides goldsteinii MTS01 alone. The murine macrophage cells were cultured by the above method, and then 0.01 ng/mL, 0.1 ng/mL, 1 ng/mL, 10 ng/mL, 100 ng/mL, 1000 ng/mL, or 10000 ng/mL of the aforementioned lipopolysaccharide of Parabacteroides goldsteinii MTS01 of the present invention was respectively added into different wells, and the same concentrations of lipopolysaccharide of E. coli O111:B4 strain were as the negative control groups. After added with the lipopolysaccharide, the murine macrophage cells were incubated at 37° C. for 24 hours, and then the same volume of cell culture supernatant from each group was taken out to be analyzed the tumor necrosis factor-α (TNF-α or TNF-alpha) by ELISA. Wherein, five replicates were performed in each group and statistical analysis was performed by one-wat ANOVA. The values of each group were expressed as ±standard deviation (*p<0.05; **p<0.01).
The results of the effect of the lipopolysaccharide of Parabacteroides goldsteinii MTS01 on macrophages alone were shown in FIG. 3A. As shown in FIG. 3A, after being treated with lipopolysaccharides of E. coli O111:B4 strains with different concentrations alone, the amount of TNF-α secreted by murine macrophage cells would increase with increasing concentration, that is, the lipopolysaccharide of pathogenic E. coli could make murine macrophage cells secrete cytokines to induce an immune response, indicating that the experimental method could indeed be used to observe the immunomodulatory properties of lipopolysaccharide on macrophages. After being treated with lipopolysaccharides of Parabacteroides goldsteinii MTS01 of the present invention with different concentrations alone, the amount of TNF-α secreted by murine macrophage cells were all approached zero and were significantly lower than those treated with E. coli O111:B4 strains at each corresponding concentration. The results indicate that the lipopolysaccharide of Parabacteroides goldsteinii MTS01 of the present invention would not stimulate macrophages to secrete TNF-α, that is, it does not induce the macrophages to produce an immune response. Therefore, the lipopolysaccharide of Parabacteroides goldsteinii MTS01 of the present invention has low endo-toxicity to individuals.
Next, in order to better understand the immunoregulatory characteristics of lipopolysaccharide of Parabacteroides goldsteinii MTS01 of the present invention on macrophages, the test of the anti-inflammatory response effect of lipopolysaccharide of Parabacteroides goldsteinii MTS01 of the present invention on macrophages was further performed. First, the murine macrophage cells were cultured by the above method, and then lipopolysaccharides of E. coli O111:B4 strain and lipopolysaccharides of Parabacteroides goldsteinii MTS01 of the present invention were added into different wells respectively with 1:0, 1:1, 1:10, 1:100, 1:1000, or 1:10000 volume ratio (ng/mL) of mixed samples. After added with the lipopolysaccharide, the murine macrophage cells were incubated at 37° C. for 24 hours, and then the same volume of cell culture supernatant from each group was taken out to be analyzed the TNF-α by ELISA. Wherein, the analysis results of each group were based on the result from 1 ng/mL of the lipopolysaccharide of E. coli O111: B4 strain. Five replicates were performed in each group and statistical analysis was performed by one-wat ANOVA. The values of each group were expressed as ±standard deviation (*p<0.05; **p<0.01).
The results of the effect of lipopolysaccharides of Parabacteroides goldsteinii MTS01 of the present invention on inhibiting the inflammatory response of macrophages were shown in FIG. 3B. As shown in FIG. 3B, after being treated with the mixed samples of 1:1 or 1:10 volume ratios (ng/mL), the amount of TNF-α secreted by murine macrophage cells was lower than that treated with the lipopolysaccharide of E. coli O111:B4 strain alone (i.e. 1:0); and after being treated with the mixed samples of 1:100, 1:1000, or 1:10000 volume ratios (ng/mL), the amount of TNF-α secreted by murine macrophage cells was significantly lower than that treated with the lipopolysaccharide of E. coli O111:B4 strain alone. The results indicate that the lipopolysaccharide of Parabacteroides goldsteinii MTS01 of the present invention can inhibit the immune response induced by the lipopolysaccharide of E. coli in macrophages, and therefore has the effect of inhibiting the inflammatory response of peripheral blood monocyte, that is, the lipopolysaccharide of Parabacteroides goldsteinii MTS01 of the present invention has the ability of immunoinhibitory, and is a potential factor for inhibiting the inflammatory response induced by E. coli.
Example 4
Effect of Parabacteroides goldsteinii on Inhibiting Inflammatory Response of B Cell
In one embodiment of the present invention, the activity test of lipopolysaccharide of Parabacteroides goldsteinii MTS01 to inhibit the inflammatory response of B cells was performed, and the test was performed with Naïve B cells. Wherein, the Naïve B cell was isolated and purified from spleen single cells of non-immune-induced mice by EasySep™ mouse B cell isolation kit (purchased from Stemcell Technologies, UK), and the recovery and purity of the isolated Naïve B cells were analyzed and confirmed by flow cytometry (FACSAria, BD, USA); wherein, the isolated and 4×107 purified Naïve B cells were re-suspended in flow cytometry staining buffer (phosphate buffered saline buffer, PBS buffer, containing 0.1 fetal bovine serum), and 5-(and-6)-carboxyfluorescein diacetate succinimidyl ester, CFDA-SE (purchased from Molecular Probes, USA) was used for Naïve B cell staining, in which CFDA-SE was added with the final concentration of 5 μM and the Naïve B cells were stained at 37° C. for 10 minutes, and upon diffusion of CFDA-SE into the cells, a highly fluorescent green dye, CFSE, will be generated. After the analysis, the Naïve B cells were immediately washed three times with cold flow cytometry staining buffer, and then the Naïve B cells were re-suspended in the cell culture medium, and were then cultured in a 24-well culture plate at a concentration of 2×106 cells/mL per well.
CFDA-SE is frequently used in cell proliferation assays, as it is partitioned approximately equally between the progeny so that cell division can be followed as a successive halving of the fluorescence intensity through multiple generational divisions; therefore, the B cell proliferation stimulated with various lipopolysaccharides doses was analyzed by flow cytometry.
According to the previous research, it is known that the Naïve B cells are induced by lipopolysaccharide to induce the Naïve B cells to perform an immune response of antigen presentation. CD86 and CD19 are B-cell-specific antigen-presenting proteins, and CD86 is only expressed after the Naïve B cell differentiation. Therefore, if the Naïve B cell produces an immune response, the expression of the surface antigens of CD86 and the cell proliferation would increase, and it would promote the differentiation of the NaïveB cell into plasma cells, which are the main cells that secrete antibodies and are larger than the Naïve B cells. In addition, if B cells produce an immune response, it would also increase the secretion of TNF-α.
In order to preliminary understand the immunoregulatory properties of lipopolysaccharide of Parabacteroides goldsteinii MTS01 of the present invention on B cells, the test was first performed to stimulate B cells with lipopolysaccharide of Parabacteroides goldsteinii MTS01 alone. After the Naïve B cells were isolated and purified by the above method, the 100 ng/mL, 1000 ng/mL, or 10000 ng/mL of the aforementioned lipopolysaccharide of Parabacteroides goldsteinii MTS01 of the present invention was respectively added into different wells, and the 100 ng/mL, 1000 ng/mL, or 10000 ng/mL of lipopolysaccharide of E. coli O111:B4 strain were as the negative control groups. After added with the lipopolysaccharide, the B cells were incubated at 37° C. for 48 hours, flow cytometry was used to analyze the size and the expression of surface antigens of CD86 and proliferation of B cells after immune induction. At the same time, the same volume of cell culture supernatant from each group was taken out to be analyzed the TNF-α secreted from B cells.
The results of the effect of the lipopolysaccharide of Parabacteroides goldsteinii MTS01 on B cells alone were shown in FIGS. 4A to 4C. As shown in FIG. 4A, after being treated with 100 ng/mL, 1000 ng/mL, and 10000 ng/mL of the lipopolysaccharides of E. coli O111:B4 strains alone, the size and the expression of surface antigens of CD86 and proliferation of B cells would increase with increasing concentration. As shown in FIGS. 4B and 4C, after being treated with 1000 ng/mL of the lipopolysaccharides of E. coli O111:B4 strains alone, 68.8% of B cells expressed surface antigen of CD86 protein, and 35.9% of B cells were proliferative, and the amount of TNF-α secreted by B cells was about 33 ng/mL. The results indicate that the lipopolysaccharide of pathogenic E. coli indeed induces immune response of the Naïve B cells, indicating that the experimental method could indeed be used to observe the immunomodulatory properties of lipopolysaccharide on B cells.
As shown in FIG. 4A, after being treated with 100 ng/mL, 1000 ng/mL, and 10000 ng/mL of the lipopolysaccharides of Parabacteroides goldsteinii MTS01 of the present invention, the size and the expression of surface antigens of CD86 of B cells were hardly changed and were significantly smaller and lower than those treated with 100 ng/mL, 1000 ng/mL, and 10000 ng/mL of E. coli O111:B4 strains. As shown in FIGS. 4B and 4C, after being treated with 1000 ng/mL or 10000 ng/mL of the lipopolysaccharides of Parabacteroides goldsteinii MTS01 of the present invention, respectively, only 2.8% and 3.5% of the B cells expressed surface antigen of CD86 protein, and only 0.2% and 0.4% of the B cells were proliferative, and the amount of TNF-α secreted by B cells approached zero, and these values were all similar to those in B cells which were not treated with any lipopolysaccharide. The results indicate that the lipopolysaccharide of Parabacteroides goldsteinii MTS01 of the present invention would not induce the differentiation and secretion of cytokines of the Naïve B cells. Therefore, the lipopolysaccharide of Parabacteroides goldsteinii MTS01 of the present invention has low endo-toxicity to individuals and would not induce immune response in Naïve B cells.
Next, in order to better understand the immunoregulatory characteristics of lipopolysaccharide of Parabacteroides goldsteinii MTS01 of the present invention on B cells, the test of the anti-inflammatory response effect of lipopolysaccharide of Parabacteroides goldsteinii MTS01 of the present invention on B cells was further performed. After the Naïve B cells were isolated and purified by the above method, the lipopolysaccharides of E. coli O111:B4 strain and lipopolysaccharides of Parabacteroides goldsteinii MTS01 of the present invention were added into different wells respectively with 1000:1000, or 1000:10000 volume ratio (ng/mL) of mixed samples. After added with the lipopolysaccharide, the B cells were incubated at 37° C. for 48 hours, the same volume of cell culture supernatant from each group was taken out to be analyzed the TNF-α secreted from B cells. At the same time, flow cytometry was used to analyze the expression of surface antigen CD86 and cell proliferation of B cells after immune induction.
The results of the effect of lipopolysaccharides of Parabacteroides goldsteinii MTS01 of the present invention on inhibiting the inflammatory response of B cells were shown in FIGS. 4B and 4C. As shown in FIGS. 4B and 4C, after being treated with the mixed samples of 1000:1000 or 1000:10000 volume ratios (ng/mL), respectively, 41.7% or 62.4% of B cells expressed surface antigen of CD86 protein, and, respectively, 18.6% or 30.4% of B cells were proliferative, and the amount of TNF-α secreted by B cells was respectively about 20 ng/mL or 36 ng/mL; wherein, the inhibition effect of the mixed samples of 1000:1000 volume ratios (ng/mL) was better than that of the mixed samples of 1000:10000 volume ratios (ng/mL). The results indicate that the lipopolysaccharide of Parabacteroides goldsteinii of the present invention can inhibit the immune response of B cells induced by the lipopolysaccharide of E. coli, indicating that the lipopolysaccharide of Parabacteroides goldsteinii of the present invention has anti-inflammatory activity on B cells.
The use of the lipopolysaccharide of the Parabacteroides goldsteinii of the present invention in the inhibition of inflammatory response can be, but is not limited to, oral administration to the subject in need thereof. The composition can be orally administered along with food; therefore, the preparation of the composition comprising the Parabacteroides goldsteinii of the present invention can further include a protein, a monosaccharide, a disaccharide, an oligosaccharide, an oligosaccharide, a polysaccharide, a carbohydrate, an amino acid, a lipid, a vitamin, or any combination thereof, and the composition further comprises a pharmaceutically acceptable excipient, carrier, adjuvant, and/or food additive.
Otherwise, the preparation of the composition comprising the lipopolysaccharide of the Parabacteroides goldsteinii of the present invention can further comprise a pharmaceutically acceptable carrier or another adjuvant well-known in the art. The composition is in the form of, but is not limited to, a spray gas, a solution, a semi-solid, a solid, a gelatin capsule, a soft capsule, a tablet, an oral strip, a chewing gum, and/or a freeze-dried powder in order to deliver the lipopolysaccharide of the Parabacteroides goldsteinii of the present invention to the intestinal tract or to partially or fully colonize to the intestinal tract of subjects. Simultaneously, the lipopolysaccharide of the Parabacteroides goldsteinii of the present invention can further use in the preparation of a food, a health food, or a dietary supplement.
In summary, the invention provides a method of inhibiting an inflammatory response, comprising administering to a subject in need thereof a composition comprising an effective amount of a lipopolysaccharide of a Parabacteroides goldsteinii. In the Parabacteroides goldsteinii of the present invention, the sequence position of orthologous gens corresponding to the gene of LpxA, LpxC, LpxD, LpxH, LpxB, LpxK, KdtA, and LpxL, to the lipid A known in E. coli could be found, except LpxM. However, these genes have low identity with E. coli MG1655 strain and Bacteroides dorei DSM17855 strain. The lipopolysaccharide of Parabacteroides goldsteinii of the present invention would not stimulate the secretion of interleukin-1β by peripheral blood mononuclear cells, the secretion of TNF-α by macrophages, and would not induce the Naïve B to express surfaces antigen CD86 and proliferation, which represent the Naïve B cells are induced to differentiate, indicating that the lipopolysaccharide of Parabacteroides goldsteinii MTS01 of the present invention would not cause an immune response in peripheral blood mononuclear cells, macrophages, or B cells, that is, it has low endo-toxicity to individuals. Furthermore, the lipopolysaccharide of Parabacteroides goldsteinii of the present invention can inhibit the immune response induced by the lipopolysaccharide of E. coli in human peripheral blood mononuclear cells, macrophages, or B cells, and has anti-inflammatory activity in peripheral blood mononuclear cells, macrophages, or B cells, and has immunosuppressive ability. Therefore, the lipopolysaccharide of Parabacteroides goldsteinii of the present invention can be used for inhibiting the immune response and the preparation of the compositions thereof, and in particular, it can inhibit the inflammatory response caused by pathogenic lipopolysaccharide.

Claims (9)

What is claimed is:
1. A method of inhibiting an inflammatory response, comprising:
administering to a subject in need thereof a composition comprising an effective amount of an isolated lipopolysaccharide from a Parabacteroides goldsteinii.
2. The method according to claim 1, wherein the isolated lipopolysaccharide inhibits an immune response of a peripheral blood mononuclear cell, a macrophage, or a B cell.
3. The method according to claim 2, wherein the isolated lipopolysaccharide inhibits the peripheral blood mononuclear cell or the macrophage secretes a cytokine.
4. The method according to claim 2, wherein the isolated lipopolysaccharide inhibits differentiation of B cells or secretion of a cytokine.
5. The method according to claim 1, wherein the inflammatory response is induced by a pathogenic lipopolysaccharide.
6. The method according to claim 5, wherein the pathogenic lipopolysaccharide is from an Escherichia coli.
7. The method according to claim 1, wherein the Parabacteroides goldsteinii is Parabacteroides goldsteinii DSM32939.
8. The method according to claim 1, wherein the composition further comprises a pharmaceutically acceptable excipient, carrier, adjuvant, or food additive.
9. The method according to claim 1, wherein the composition is in a form of a spray, a solution, a semi-solid state, a solid state, a gelatin capsule, a soft capsule, a tablet, an oral strip, a chewing gum or a freeze-dried powder.
US16/747,904 2019-01-25 2020-01-21 Method of inhibiting inflammatory response using lipopolysaccharide of Parabacteroides goldsteinii Active US11253541B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US16/747,904 US11253541B2 (en) 2019-01-25 2020-01-21 Method of inhibiting inflammatory response using lipopolysaccharide of Parabacteroides goldsteinii

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962796599P 2019-01-25 2019-01-25
TW108148713 2019-12-31
TW108148713A TWI716249B (en) 2019-01-25 2019-12-31 Use of lipopolysaccharide of parabacteroides goldsteinii to inhibit inflammation
US16/747,904 US11253541B2 (en) 2019-01-25 2020-01-21 Method of inhibiting inflammatory response using lipopolysaccharide of Parabacteroides goldsteinii

Publications (2)

Publication Number Publication Date
US20200237806A1 US20200237806A1 (en) 2020-07-30
US11253541B2 true US11253541B2 (en) 2022-02-22

Family

ID=71733187

Family Applications (1)

Application Number Title Priority Date Filing Date
US16/747,904 Active US11253541B2 (en) 2019-01-25 2020-01-21 Method of inhibiting inflammatory response using lipopolysaccharide of Parabacteroides goldsteinii

Country Status (1)

Country Link
US (1) US11253541B2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220175821A1 (en) * 2020-10-27 2022-06-09 Multistars Biotechnology Company Limited Methods for improving anti-oxidation and preventing/treating diseases using hypo-acylated lipopolysaccharide

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113651896B (en) * 2021-07-09 2022-07-12 中山大学 Bacteroides dychii extracellular polysaccharide and extraction method and application thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Neyrinck, A. et al "Rhubarb extract prevents hepatic inflammation . . . " Mol. Nutr. Food Res., vol. 61, No. 1, pp. 1-12. (Year: 2017). *
Wu, T. et al "Gut commensal Parabacteroides goldsteinii plays a predominant role . . . " Gut, vol. 68, pp. 248-262. (Year: 2019). *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220175821A1 (en) * 2020-10-27 2022-06-09 Multistars Biotechnology Company Limited Methods for improving anti-oxidation and preventing/treating diseases using hypo-acylated lipopolysaccharide

Also Published As

Publication number Publication date
US20200237806A1 (en) 2020-07-30

Similar Documents

Publication Publication Date Title
Nyangale et al. Bacillus coagulans GBI-30, 6086 modulates Faecalibacterium prausnitzii in older men and women
López et al. Distinct Bifidobacterium strains drive different immune responses in vitro
Zeuthen et al. Lactic acid bacteria inducing a weak interleukin-12 and tumor necrosis factor alpha response in human dendritic cells inhibit strongly stimulating lactic acid bacteria but act synergistically with gram-negative bacteria
Karamese et al. The immunostimulatory effect of lactic acid bacteria in a rat model
KR101042123B1 (en) Selection and use of lactic acid bacteria for reducing inflammation in mammals
CN110870859B (en) Probiotic metabolites for delaying signs of aging
Kuo et al. Immunomodulatory effect of exo-polysaccharides from submerged cultured Cordyceps sinensis: enhancement of cytokine synthesis, CD11b expression, and phagocytosis
Strompfová et al. Effect of Bifidobacterium animalis B/12 administration in healthy dogs
JP6337262B2 (en) Salt-resistant lactic acid bacteria, culture method of salt-resistant lactic acid bacteria, and immunostimulant
US11253541B2 (en) Method of inhibiting inflammatory response using lipopolysaccharide of Parabacteroides goldsteinii
JPWO2006093313A1 (en) T cell apoptosis inducer
EP2220210B1 (en) Strains of lactobacillus plantarum as probiotics with immunomodulatory specific effect
WO2021143621A1 (en) Anaerostipes sp b2131 strain and use thereof in inflammatory bowel diseases
JP7358001B2 (en) Lactic acid bacteria, interleukin-22 production inducer, skin barrier function enhancer
KR102525173B1 (en) Bacillus bacteria, interleukin-22 production inducer, skin barrier function enhancer
Guarner The enteric microbiota
TWI716249B (en) Use of lipopolysaccharide of parabacteroides goldsteinii to inhibit inflammation
CN111494431B (en) Application of probiotics in preparation of preparation for treating liver diseases
Rolny et al. Lactobacillus delbrueckii subsp lactis CIDCA 133 modulates response of human epithelial and dendritic cells infected with Bacillus cereus.
CN103224895B (en) Novel lactobacillus lodelbrueckii strain and application thereof in improving autoimmune diseases
Mourey et al. The probiotic strain Bacillus subtilis CU1 primes antimicrobial innate immune response and reduces low-grade inflammation: a clinical study
CN118161534B (en) Fuglesen escherichia and use of product thereof in inflammatory diseases
WO2024107835A2 (en) Probiotic formulations and methods of use thereof
CN118685294A (en) Mycobacterium fumosoroseum and application thereof in treating asthma
CN118109353A (en) Pediococcus acidilactici strain and application thereof

Legal Events

Date Code Title Description
AS Assignment

Owner name: MULTISTARS BIOTECHNOLOGY COMPANY LIMITED, TAIWAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LIN, TZU-LUNG;WU, PO-I;REEL/FRAME:051652/0270

Effective date: 20191028

FEPP Fee payment procedure

Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

FEPP Fee payment procedure

Free format text: ENTITY STATUS SET TO SMALL (ORIGINAL EVENT CODE: SMAL); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS

STPP Information on status: patent application and granting procedure in general

Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT RECEIVED

STPP Information on status: patent application and granting procedure in general

Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT VERIFIED

STCF Information on status: patent grant

Free format text: PATENTED CASE